1/5/2010

Adventrx Pharmaceuticals filed for FDA approval to launch ANX-530, a chemotherapy drug for breast cancer and non-small cell lung cancer. The treatment has clinically shown bioequivalence to GlaxoSmithKline's Navelbine without the side effect of vein irritation after intravenous delivery.

Related Summaries